De Corso E, et al. – In this study involving patients with nonallergic rhinitis eosinophilic syndrome (NARES), researchers determined the efficacy of montelukast in improving oculonasal symptoms, patient-reported outcomes, and eosinophilic biomarkers. Participants included 80 symptomatic patients who were enrolled prospectively and were treated with 10 mg of montelukast once daily as monotherapy for 2 months. The investigators used the visual analogic scale to score nasal and ocular symptoms, and patient-reported outcomes. Before and after treatment assessments were carried out in all patients. According to findings, montelukast may offer a therapeutic benefit for patients with NARES. Specifically, a greater efficacy could be predicted by the presence of concomitant asthma.